NewCardio Inc (NWCI) Prix

NewCardio, Inc. is a cardiac diagnostic technology provider, which focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular diseases, as well as the cardiac safety assessment of drugs under development. The company is headquartered in Santa Clara, California and currently employs 10 full-time employees. The company went IPO on 2006-11-03. The firm is focused on the development of a platform technology for its products, which will improve the diagnostic accuracy and value of the standard 12-lead electrocardiogram (ECG). The Company’s core technology platform provides real-time, three-dimensional (3D) analysis of the heart's electrical activity, as detected at the body surface by standard 12-lead ECG electrodes. ECG input signals are typically sampled at 500 hertz (500 times per second).